These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 8976824)
1. The role of HIV-proteinase inhibitors. Gazzard B; Moyle G Genitourin Med; 1996 Aug; 72(4):233-5. PubMed ID: 8976824 [No Abstract] [Full Text] [Related]
2. [Synthetic HIV proteinase inhibitors and new prospects for drug therapy of HIV infections and AIDS]. Galegov GA Vopr Virusol; 1997; 42(6):284-6. PubMed ID: 9499245 [No Abstract] [Full Text] [Related]
3. Data in from first head-to-head protease inhibitor. AIDS Patient Care STDS; 1998 Apr; 12(4):317. PubMed ID: 11361961 [No Abstract] [Full Text] [Related]
4. Anti-HIV effects of nelfinavir reported after ten months of combination therapy. AIDS Patient Care STDS; 1997 Aug; 11(4):289-90. PubMed ID: 11361848 [No Abstract] [Full Text] [Related]
6. A controlled trial of double versus triple therapy for HIV. Delgado Fernández M; Zambrana García JL; Díez García F N Engl J Med; 1998 Jan; 338(3):197. PubMed ID: 9441226 [No Abstract] [Full Text] [Related]
7. [Antiretroviral therapy in patients infected with HIV-1]. Corti ME Medicina (B Aires); 1998; 58 Suppl 1():49-56. PubMed ID: 9674248 [No Abstract] [Full Text] [Related]
8. Anti-HIV effects of Viracept persist during long periods of combination therapy. Oncology (Williston Park); 1997 Jun; 11(6):915. PubMed ID: 9189946 [No Abstract] [Full Text] [Related]
9. DMP 266 and indinavir combination. AIDS Patient Care STDS; 1997 Aug; 11(4):287-8. PubMed ID: 11361845 [No Abstract] [Full Text] [Related]
10. Developing long-term treatment strategies. PI Perspect; 1996 Sep; (No 19):11-4. PubMed ID: 11363897 [TBL] [Abstract][Full Text] [Related]
14. Genotypic resistance and the treatment of HIV-1 infection in Espírito Santo, Brazil. Pilcher CD; Perkins MD; Fiscus SA; Johnston DM; Dietze R; Duque UH; Zago AM; Assad-Antunes F; Eron JJ J Infect Dis; 1999 May; 179(5):1259-63. PubMed ID: 10191233 [TBL] [Abstract][Full Text] [Related]
15. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. Deeks SG; Wrin T; Liegler T; Hoh R; Hayden M; Barbour JD; Hellmann NS; Petropoulos CJ; McCune JM; Hellerstein MK; Grant RM N Engl J Med; 2001 Feb; 344(7):472-80. PubMed ID: 11172188 [TBL] [Abstract][Full Text] [Related]
16. A controlled trial of double versus triple therapy for HIV. Feldmesser M; Falkenberg J N Engl J Med; 1998 Jan; 338(3):196; author reply 197. PubMed ID: 9441224 [No Abstract] [Full Text] [Related]
17. Saquinavir for treatment of patients with HIV. Am Fam Physician; 1996 Feb; 53(2):782, 785. PubMed ID: 8629551 [No Abstract] [Full Text] [Related]
18. Protease inhibitors: implications for HIV research and treatment. Churchill SA J Int Assoc Physicians AIDS Care; 1996 Jan; 2(1):13-8. PubMed ID: 11363325 [TBL] [Abstract][Full Text] [Related]
19. Salvage therapy for patients failing their current antiretroviral regimen. Albrecht MA AIDS Clin Rev; 2000-2001; ():139-91. PubMed ID: 10999220 [No Abstract] [Full Text] [Related]
20. Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies. Erickson JW; Gulnik SV; Markowitz M AIDS; 1999; 13 Suppl A():S189-204. PubMed ID: 10885776 [No Abstract] [Full Text] [Related] [Next] [New Search]